Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 cr
Glenmark Pharmaceuticals experienced a 56.78 percent drop in consolidated profit after tax during the September quarter. Total revenue from operations decreased to Rs 4,247.32 crore compared to the previous year. The company's total expenses also decreased during the same period, indicating some operational efficiency. A subsidiary of Glenmark Pharma entered into a settlement for USD 15...
Key Takeaways
- Glenmark Pharmaceuticals experienced a 56.78 percent drop in consolidated profit after tax during the September quarter.
- Total revenue from operations decreased to Rs 4,247.32 crore compared to the previous year.
- The company's total expenses also decreased during the same period, indicating some operational efficiency.
Glenmark Pharmaceuticals experienced a 56.78 percent drop in consolidated profit after tax during the September quarter. Total revenue from operations decreased to Rs 4,247.32 crore compared to the previous year. The company's total expenses also decreased during the same period, indicating some operational efficiency. A subsidiary of Glenmark Pharma entered into a settlement for USD 15 million with Humana Inc.
Original Publisher Attribution
This summary was curated from Economic Times.